Evaluation of drug‐induced QT interval prolongation in animal and human studies: a literature review of concordance

Evaluating whether a new medication prolongs QT intervals is a critical safety activity that is conducted in a sensitive animal model during non‐clinical drug development. The importance of QT liability detection has been reinforced by non‐clinical [International Conference on Harmonization ( ICH ) S 7 B ] and clinical ( ICH E 14) regulatory guidance from the I nternational C onference on H armonization. A key challenge for the cardiovascular safety community is to understand how the finding from a non‐clinical in vivo   QT assay in animals predicts the outcomes of a clinical QT evaluation in humans. The H ealth and Environmental S ciences I nstitute P ro‐ A rrhythmia W orking G roup performed a literature search (1960–2011) to identify both human and non‐rodent animal studies that assessed QT signal concordance between species and identified drugs that prolonged or did not prolong the QT interval. The main finding was the excellent agreement between QT results in humans and non‐rodent animals. Ninety‐one percent (21 of 23) of drugs that prolonged the QT interval in humans also did so in animals, and 88% (15 of 17) of drugs that did not prolong the QT interval in humans had no effect on animals. This suggests that QT interval data derived from relevant non‐rodent models has a 90% chance of predicting QT findings in humans. Disagreement can occur, but in the limited cases of QT discordance we identified, there appeared to be plausible explanations for the underlying disconnect between the human and non‐rodent animal QT outcomes.